Bagel, J., Armstrong, A. ., Warren, R., Papp, K., Thaçi, D., Menter, A., Cather, J., Augustin, M., Hippeli, L., Daamen, C. and Griffiths, C. (2022) “Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial”, SKIN The Journal of Cutaneous Medicine, 6(6), p. s47. doi: 10.25251/skin.6.supp.47.